Active Ingredient History

  • Now
Abexinostat is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.   Wikipedia

  • SMILES: CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc3ccc(cc3)C(=O)NO
  • Mol. Mass: 397.43
  • ALogP: 2.42
  • ChEMBL Molecule:
More Chemistry
abexinostat | cra024781 | cra 024781 | cra-024781 | cra-24781 | pci24781 | pci 24781 | pci-24781 | s-78454


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue